referred to were all in vivo and thus could not provide any evidence that nitrous oxide was an agonist at opiate receptors rather than an agent acting indirectly by releasing an endogenous opioid. Our own recent work (Thomas et al. 1981) would support this latter possibility as it demonstrates, in obstetric patients, that nitrous oxide increases plasma opioid levels whereas pethidine, a known opiate agonist, reduces them.
The paradoxical effects of naloxone were deliberately omitted from my reviewas more likely to cause confusion than enlightenment, but here too I would disagree with the conclusions of Gillman and his colleague. On the subject of the production of analgesia by naloxone they misquote their own studies which did not show analgesia but only a weak potentiation of the effects of either nitrous oxide or morphine, and although the other studies referred to did reveal a measure of analgesia with naloxone alone, this is far from being a universal observation (see Sawynok et al. 1979) . It is not true to say that naloxone is completely without agonist effects and these have now been reported by several groups of workers (see Sawynok et al. 1979) . The biphasic effect of naloxone seen by Woolf (1980) in the rat and by Levine et al. (1979) in their clinical study is of great interest, but such an effect was not apparent in the single-dose studies of Gillman and his co-workers and thus citations of this work here are inappropriate. Yang et al. (1980) took great pains to point out in their paper that 'in 8 subjects naloxone, 8 mg, administered without nitrous oxide, had no effects on pain report' and the reasons for quoting this paper in support of naloxone-produced hyperalgesia escape me. Restricting ourselves to the careful work of Woolf (1980) and Levine et al. (1979) , it is possible to explain the biphasic action of naloxone without the expedient of an endogenous 'anti-opioid' system. Woolf raised the possibility of a low dose of naloxone having a partial agonist action at a subpopulation of opiate receptors or, alternatively, acting to disinhibit an endogenous analgesic system. The recognition of multiple opiate receptors with differing sensitivities to naloxone and located at different sites within the central nervous system (Herkenham & Pert 1980) provides the underlying circuitry for such effects. A more parsimonious explanation still is that, in the presence of appreciable amounts of endogenous opioid sufficient to cause receptor desensitization, an apparent analgesia would result from the administration of low concentrations of naloxone due to a reduction in the acute desensitization of the receptor. At higher concentrations of naloxone then a classical antagonism would take over and lead to hyperalgesia. Such a mechanism has been described previously at the GADA receptor (Krnjevic et al. 1977 ,Simmonds 1978 
